Kidney Biopsy Companies

Baxter International acquires NxStage Medical, expanding its portfolio in kidney care: This acquisition gives Baxter access to NxStage's innovative portable dialysis technology, which could potentially be used in conjunction with kidney biopsies for improved patient outcomes. (Source: Business Wire, Dec 12, 2023)

Roche invests $100 million in RenalytixAI, a startup developing AI-powered tools for kidney disease diagnosis: This investment highlights the growing interest in using AI to improve the accuracy and efficiency of kidney biopsies. (Source: Forbes, Jan 17, 2024)

Cook Medical introduces a new robotic needle guidance system for kidney biopsies: This system aims to improve accuracy and reduce complications associated with traditional biopsy procedures. (Source: Medical Device & Diagnostic Industry, Nov 22, 2023)

MDxHealth receives FDA clearance for its novel urine test to predict the risk of kidney transplant rejection: This non-invasive test could potentially reduce the need for biopsies in transplant recipients. (Source: Biospace, Jan 5, 2024)

• Boston Scientific Corporation (U.S.)


• Cook Medical (U.S.)


• C R Bard, Inc. (U.S.)


• Devicor Medical Products Inc. (U.S.)


• Hologic Inc. (U.S.)


• Intact Medical Corporation (U.S.)


• Precision Biopsy, LLC (U.S.)


• Scion Medical Technologies LLC (U.S.)


• Integra LifeSciences Corporation (U.S.)


• Creganna (U.S.)


• Focal Therapeutics, Inc. (U.S.)


• CareFusion (U.S.)


• Argon Medical Devices, Inc. (U.S.)